Source comparison
Bioavailability Comparison
Standard oral BPC-157 suffers approximately 97% degradation in the digestive system, leaving only about 3% of the original compound available for therapeutic use. This poor bioavailability means oral users must take significantly higher doses to achieve meanin
This comparison does not assign a generated winner or score.
- Standard oral BPC-157 suffers approximately 97% degradation in the digestive system, leaving only about 3% of the original compound available for therapeutic use. This poor bioavailability means oral users must take significantly higher doses to achieve meaningful tissue levels. Injectable BPC-157, administered subcutaneously, bypasses digestive degradation entirely and delivers the full dose to systemic circulation.
- BPC-157 arginate, a newer formulation that complexes the peptide with L-arginine, achieves better oral bioavailability around 90%. However, this form costs more and remains less available than standard acetate preparations. For most CrossFit athletes, injectable acetate BPC-157 offers the best combination of effectiveness, cost, and availability.